Literature DB >> 6341126

Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice.

P R Flatt, C J Bailey, P Kwasowski, S K Swanston-Flatt, V Marks.   

Abstract

The role of GIP in the pathogenesis of spontaneous syndromes of obesity-diabetes was examined in ob/ob mice of the Aston stock and db/db mice of the C57BL/KsJ background. Compared with lean controls, fed adult ob/ob and db/db mice, respectively, exhibited 1.8-fold and 2.1-fold increases in body weight, 1.8-fold and 2.8-fold elevations of plasma glucose, and 15.4-fold and 5.6-fold elevations of plasma insulin. As indicated by the relative magnitude of the hyperglycemia and hyperinsulinemia, db/db mice displayed a particularly severe form of diabetes. Plasma GIP concentrations of ob/ob and db/db mice were elevated 15.1-fold and 6.2-fold, respectively; the increments closely corresponded with the degrees of hyperinsulinemia. Small intestinal weight was increased 1.4-fold and 1.8-fold in ob/ob and db/db mice, respectively, but the intestinal GIP content expressed as microgram/g intestine or microgram/intestine was raised only in ob/ob mice (1.9-fold and 2.8-fold, respectively). Since glucose stimulation of insulin release is defective in both mutant strains, the results strongly implicate pathologically raised GIP concentrations in the hyperinsulinemia and related metabolic abnormalities of the obesity-diabetes syndromes. It is suggested that hypersecretion of GIP results in part from loss of normal feedback inhibition by endogenous insulin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6341126     DOI: 10.2337/diab.32.5.433

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  24 in total

1.  Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.

Authors:  N Irwin; P L McClean; F P M O'Harte; V A Gault; P Harriott; P R Flatt
Journal:  Diabetologia       Date:  2007-05-08       Impact factor: 10.122

2.  Gut Hormone GIP Induces Inflammation and Insulin Resistance in the Hypothalamus.

Authors:  Yukiko Fu; Kentaro Kaneko; Hsiao-Yun Lin; Qianxing Mo; Yong Xu; Takayoshi Suganami; Peter Ravn; Makoto Fukuda
Journal:  Endocrinology       Date:  2020-09-01       Impact factor: 4.736

3.  RNA-Seq analysis of enteroendocrine cells reveals a role for FABP5 in the control of GIP secretion.

Authors:  Cesar A Sommer; Gustavo Mostoslavsky
Journal:  Mol Endocrinol       Date:  2014-09-30

4.  Comparative Intracerebroventricular and Intrathecal Administration of a Nanomolar Macrocyclic Melanocortin Receptor Agonist MDE6-5-2c (c[Pro-His-DPhe-Arg-Trp-Dap-Ala-DPro]) Decreases Food Intake in Mice.

Authors:  Danielle N Adank; Mary M Lunzer; Mark D Ericson; Zoe M Koeperich; Stacey L Wilber; Katlyn A Fleming; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2020-09-10       Impact factor: 4.418

5.  Increased responsiveness to glucoregulatory effect of opiates in obese-diabetic ob/ob mice.

Authors:  C J Bailey; P R Flatt
Journal:  Diabetologia       Date:  1987-01       Impact factor: 10.122

6.  High-fat feeding stimulates endocrine, glucose-dependent insulinotropic polypeptide (GIP)-expressing cell hyperplasia in the duodenum of Wistar rats.

Authors:  D Gniuli; A Calcagno; L Dalla Libera; R Calvani; L Leccesi; M E Caristo; R Vettor; M Castagneto; G Ghirlanda; G Mingrone
Journal:  Diabetologia       Date:  2010-06-30       Impact factor: 10.122

Review 7.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

8.  Gastric inhibitory polypeptide (GIP) hypersecretion in obesity depends on meal size and is not related to hyperinsulinemia.

Authors:  R Ebert; W Creutzfeldt
Journal:  Acta Diabetol Lat       Date:  1989 Jan-Mar

9.  A case-control analysis of common variants in GIP with type 2 diabetes and related biochemical parameters in a South Indian population.

Authors:  Divya Sugunan; Anup K Nair; Harish Kumar; Anilkumar Gopalakrishnapillai
Journal:  BMC Med Genet       Date:  2010-07-30       Impact factor: 2.103

10.  (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy.

Authors:  P L McClean; N Irwin; K Hunter; V A Gault; P R Flatt
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.